{"title":"长效注射丁丙诺啡-澳大利亚囚犯的“最佳实践”阿片类药物激动剂治疗。","authors":"Russ Scott, Andrew Aboud, Thomas O'Gorman","doi":"10.1177/10398562211059086","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To consider opioid agonist therapy in prisons.</p><p><strong>Conclusions: </strong>Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as 'best practice' treatment in Australian prison populations.</p>","PeriodicalId":347122,"journal":{"name":"Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists","volume":" ","pages":"498-502"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Long-acting injectable buprenorphine - 'best practice' opioid agonist therapy for Australian prisoners.\",\"authors\":\"Russ Scott, Andrew Aboud, Thomas O'Gorman\",\"doi\":\"10.1177/10398562211059086\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To consider opioid agonist therapy in prisons.</p><p><strong>Conclusions: </strong>Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as 'best practice' treatment in Australian prison populations.</p>\",\"PeriodicalId\":347122,\"journal\":{\"name\":\"Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists\",\"volume\":\" \",\"pages\":\"498-502\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/10398562211059086\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/12/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10398562211059086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/12/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Long-acting injectable buprenorphine - 'best practice' opioid agonist therapy for Australian prisoners.
Objective: To consider opioid agonist therapy in prisons.
Conclusions: Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as 'best practice' treatment in Australian prison populations.